search
Back to results

Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients

Primary Purpose

Patient Compliance

Status
Unknown status
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
Levocarnitine
Sponsored by
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patient Compliance focused on measuring Fatigue, Levocarnitine,

Eligibility Criteria

20 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

i. Clinical diagnosis of primary hypothyroidism patients with fatigue symptoms ii. Age : From 20 to 50 years iii. Levothyroxine treatment: receiving for at least 6 months iv. Serum free thyroxine level: 0.80-1.80 ng/dl v. Serum Thyroid-stimulating hormone level: 0.35-5.50 µIU/ml ( µIU = micro international unit)

-

Exclusion Criteria:

i. Patients with Hypothyroidism 20 years and 50 years ii. Acute or chronic liver diseases iii. Anaemia iv. Clinical diagnosis of Diabetes mellitus. v. Cardiovascular disease ( such as heart failure, arrhythmia and uncontrolled hypertension ) vi. Patients with psychological disorders (such as depression, anxiety disorder, schizophrenia, alcoholism or fatigue disorder due to other systemic diseases) vii. Patients having serious infections or terminal illness (such as tuberculosis, HIV or malignant tumor ) viii. Autoimmune diseases ( such as rheumatoid arthritis, Systemic lupus erythematosus or multiple sclerosis) ix. Patients with impaired renal function x. Pregnant or planned to be pregnant xi. Nursing mothers

-

Sites / Locations

  • Phamacology Department, BSMMURecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control group

Intervention group

Arm Description

Control group - patients with only levothyroxine therapy

Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy

Outcomes

Primary Outcome Measures

Fatigue score
Alleviation of fatigue level

Secondary Outcome Measures

Lipid profile
Effect of Levocarnitine on lipid level

Full Information

First Posted
December 10, 2017
Last Updated
December 21, 2017
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
search

1. Study Identification

Unique Protocol Identification Number
NCT03372772
Brief Title
Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients
Official Title
Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Unknown status
Study Start Date
March 16, 2017 (Actual)
Primary Completion Date
December 30, 2017 (Anticipated)
Study Completion Date
February 28, 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
It has been observed that despite administration of apparently adequate thyroid hormone replacement in hypothyroid patients, many of them experience persistent fatigue and fatigue-related symptoms. Carnitine transports long chain fatty acids into the mitochondria whereupon the high energy source (ATP) becomes synthesized. Levocarnitine administration reduced fatigue related symptoms in hypothyroid patients receiving thyroid hormone replacement. The present study deals with alleviation of fatigue in hypothyroid patients by carnitine supplementation.
Detailed Description
It has been well-established now-a-days that, some chronic diseases impose generalized weakness, lethargy, lassitude amounting from degrees mild, moderate to a severe one to total incapacitation on the part of the patients. Hypothyroid patients instate of receiving adequate thyroid hormone replacement, experience fatigue-related symptoms. Carnitine is a non-essential amino acid synthesized endogenously from essential amino acids- lysine and methionine with in the body involved in long chain fatty acid transportation to the mitochondrial membrane. Carnitine- transportation system is essential for production of energy at cellular level. Thyroid hormone plays an important role in carnitine-dependent long chain fatty acid transport and oxidation. Some available reports suggest that, Levocarnitine supplementation produced potentially favourable effects on fatigue-related symptoms in hypothyroid patients although still awaits confirmation. The present study is an attempt to investigate into the effects of Levocarnitine supplementation on fatigue in patients with hypothyroidism.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patient Compliance
Keywords
Fatigue, Levocarnitine,

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Control Group- Patients with only levothyroxine therapy Interventional Group- Patients with Levocarnitine supplementation in addition to levothyroxine therapy
Masking
Participant
Masking Description
Single Blind
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
Control group - patients with only levothyroxine therapy
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
Intervention Type
Drug
Intervention Name(s)
Levocarnitine
Other Intervention Name(s)
Levocarnitine syrup
Intervention Description
Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
Primary Outcome Measure Information:
Title
Fatigue score
Description
Alleviation of fatigue level
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Lipid profile
Description
Effect of Levocarnitine on lipid level
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: i. Clinical diagnosis of primary hypothyroidism patients with fatigue symptoms ii. Age : From 20 to 50 years iii. Levothyroxine treatment: receiving for at least 6 months iv. Serum free thyroxine level: 0.80-1.80 ng/dl v. Serum Thyroid-stimulating hormone level: 0.35-5.50 µIU/ml ( µIU = micro international unit) - Exclusion Criteria: i. Patients with Hypothyroidism 20 years and 50 years ii. Acute or chronic liver diseases iii. Anaemia iv. Clinical diagnosis of Diabetes mellitus. v. Cardiovascular disease ( such as heart failure, arrhythmia and uncontrolled hypertension ) vi. Patients with psychological disorders (such as depression, anxiety disorder, schizophrenia, alcoholism or fatigue disorder due to other systemic diseases) vii. Patients having serious infections or terminal illness (such as tuberculosis, HIV or malignant tumor ) viii. Autoimmune diseases ( such as rheumatoid arthritis, Systemic lupus erythematosus or multiple sclerosis) ix. Patients with impaired renal function x. Pregnant or planned to be pregnant xi. Nursing mothers -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Farjana Akhter, MBBS
Phone
01534615464
Email
polynoble@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jasmine Dewan, PHD
Phone
01712533169
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Farjana Akhter, MBBS
Organizational Affiliation
Resident ,Phase-B
Official's Role
Principal Investigator
Facility Information:
Facility Name
Phamacology Department, BSMMU
City
Dhaka
State/Province
Shahbag
ZIP/Postal Code
1000
Country
Bangladesh
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Farjana Akhter, MBBS
Phone
01534615464
Email
polynoble@gmail.com
First Name & Middle Initial & Last Name & Degree
Jasmine Dewan, PHD
Phone
01712533169

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients

We'll reach out to this number within 24 hrs